⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL5494530 | 0.78 | TSHR (0.52) | — | |
| SCHEMBL26766 | 0.73 | — | — | |
| SCHEMBL7640768 | 0.73 | — | — | |
| SCHEMBL6595154 | 0.73 | — | — | |
| SCHEMBL181160 | 0.73 | TSHR (0.55) | — | |
| SCHEMBL276567 | 0.73 | — | — | |
| Bicarbonate SCHEMBL28022644 | 0.72 | TSHR (0.41) | — | |
| SCHEMBL10455659 | 0.71 | TSHR (0.52) | — | |
| SCHEMBL337233 | 0.71 | TSHR (0.52) | — | |
| SCHEMBL6557046 | 0.71 | TSHR (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022648-A1 | THERAPEUTIC AGENT FOR MEIBOMIAN GLAND DYSFUNCTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-01-28 | — | — | US | claimed |
| EP-2974728-A1 | THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION | Santen Pharmaceutical Co., Ltd (JP) | 2016-01-20 | — | — | EP | claimed |
| EP-1216251-B1 | REGIOSELECTIVE SYNTHESIS OF RAPAMYCIN DERIVATIVES | WYETH CORP (US) | 2003-02-26 | — | — | EP | claimed |
| US-11951098-B2 | Therapeutic agent for meibomian dysfunction | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20230190716-A1 | THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-11612590-B2 | Therapeutic agent for meibomian dysfunction | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-03-28 | — | — | US | disclosed |
| EP-3689348-A1 | THERAPEUTIC AGENT FOR MEIBOMIAN GLAND DYSFUNCTION | Santen Pharmaceutical Co., Ltd. (JP) | 2020-08-05 | — | — | EP | disclosed |
| EP-2974728-B1 | THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION | SANTEN PHARMACEUTICAL CO LTD (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-20190255026-A1 | THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20180021314-A1 | THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2018-01-25 | — | — | US | disclosed |
| US-20160022648-A1 | THERAPEUTIC AGENT FOR MEIBOMIAN GLAND DYSFUNCTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| EP-2974728-A1 | THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION | Santen Pharmaceutical Co., Ltd (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2660241-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-2651916-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| WO-2012083112-A2 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-1216251-B1 | REGIOSELECTIVE SYNTHESIS OF RAPAMYCIN DERIVATIVES | WYETH CORP (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1216251-A2 | REGIOSELECTIVE SYNTHESIS OF RAPAMYCIN DERIVATIVES | Wyeth (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001023395-A2 | REGIOSELECTIVE SYNTHESIS OF RAPAMYCIN DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |